News Related to Theranostics

CT-Based Biomarker Improves Gastric Cancer Prognosis; PET Imaging Market Grows; Neuroendocrine Tumor Research Advances

Jun 24, 2026

Brazilian researchers developed a CT-based biomarker called VMD that combines visceral fat and muscle radiodensity to predict gastric cancer prognosis, with patient survival ranging from 13.8 to 58.5 months. The global PET imaging market is projected to grow to $1.4 billion by 2032 as cancer cases rise globally. Neuroendocrine tumor research is advancing with new funding and studies on Hedgehog signaling pathways.

Stanford Launching Compact Proton Therapy; Kansas City Planning Integrated Theranostics Center

Jun 03, 2026

Stanford Medicine Cancer Center is set to launch a first-of-its-kind compact proton therapy system this summer, offering precise tumor targeting with reduced side effects. In Kansas City, a multi-institution collaboration plans to establish one of the nation's first fully integrated theranostics platforms combining research, diagnostics, and targeted radiopharmaceutical treatments for both adults and children.

Three Pharmaceutical Markets Project Strong Growth Through 2031-2032

Mar 12, 2026

New market reports forecast significant expansion in CAR T-cell therapy, US pharmaceutical drug delivery, and healthcare nanotechnology sectors, driven by chronic disease prevalence and technological advances.